Resveratrol
SupplementThe medical score is slightly higher than the community score: clinical meta-analyses document moderate metabolic effects [s10, s11], while the biohacking community predominantly reports no subjectively perceptible short-term effects [c1, c2], reflecting the low bioavailability and lack of everyday-relevant surrogate endpoints [s3].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Resveratrol is the textbook example of a supplement that shines in the petri dish and disappoints in humans: SIRT1 activation, NF-κB inhibition, and lifespan extension in model organisms sound compelling, but robust human RCTs are lacking — and oral bioavailability of ~0.5% makes any dosing discussion largely academic. David Sinclair's popularisation raised expectations the evidence simply cannot support; community sentiment reflects this disillusionment (38% positive). The EU Novel Food authorisation caps the recommended daily dose at 150 mg — far below amounts used in studies. Those invested in longevity stacks will currently find better-supported options in NMN or pterostilbene.
Description
Polyphenol from grape skins and Japanese knotweed with antioxidant, cardiovascular, and SIRT1-activating effects; low oral bioavailability (~0.5%) [s3, s4].
Resveratrol (3,5,4'-trihydroxystilbene) is a naturally occurring polyphenol of the stilbene class, found in grape skins, red wine, Japanese knotweed (Fallopia japonica), peanuts, and berries [s3]. The biologically relevant form is the trans-isomer (trans-resveratrol), which is more stable and more potent than the cis-isomer [s5]. Although resveratrol is well absorbed after oral ingestion, extensive glucuronidation and sulfation occur in the intestine and liver, resulting in very low systemic bioavailability of approximately 0.5% [s3]. Various formulation approaches—including liposomal systems, micelles, and combination with piperine—are being investigated to enhance bioavailability [s6, s7]. In preclinical studies, resveratrol activates the NAD+-dependent deacetylase SIRT1, inhibits NF-κB signaling pathways, and acts as an antioxidant [s8, s9]. Clinical studies show moderate effects on cardiovascular and metabolic risk markers (blood pressure, blood lipids, insulin resistance) in various patient populations, but with inconsistent results [s10, s11]. In the area of cognition, Phase 2 trials are currently ongoing (including the REVAMP Trial 2024); existing RCT data show limited and partly contradictory results [s12, s13]. The Alzheimer's study (Turner et al. 2015) demonstrated safety and tolerability, but no significant cognitive endpoints [s13]. Long-term effects in healthy individuals remain insufficiently established.
Legal Status (DE)
In the EU, synthetic trans-resveratrol (≥99% purity) and trans-resveratrol from microbial sources (e.g., Saccharomyces cerevisiae) are authorized as novel foods under Regulation (EU) 2015/2283, with a recommended maximum dose of 150 mg/day for adults [s1]. In Germany, resveratrol is marketable as an over-the-counter food supplement (NEM) under the LFGB framework, provided the novel food authorization is complied with [s2]. No EFSA-approved health claims are in place.
Mechanism of Action
Resveratrol acts through multiple molecular targets [s8, s9]: 1. SIRT1 activation: Resveratrol activates the NAD+-dependent enzyme Sirtuin-1 (SIRT1), which regulates histone deacetylases and triggers caloric restriction-like signaling pathways. Preclinically, lifespan extension was demonstrated in yeast (70%), worms, and Drosophila [s9]. Clinical SIRT1 effects in humans are documented in a systematic review, albeit with moderate effect size [s14]. 2. NF-κB inhibition / anti-inflammatory effects: Resveratrol inhibits the transcription factor NF-κB, thereby reducing the expression of pro-inflammatory cytokines (IL-6, TNF-α, COX-2) [s8]. 3. Antioxidant activity: Direct free radical scavenging as well as upregulation of the Nrf2 cascade with induction of antioxidant enzymes (SOD, catalase, GPx) [s8]. 4. Insulin sensitization / glucose metabolism: Resveratrol activates AMPK, inhibits phosphodiesterases, and increases mitochondrial biogenesis via PGC-1α, contributing to improved insulin sensitivity [s10, s11]. 5. Cardiovascular effects: Inhibition of platelet aggregation, reduction of LDL oxidation, blood pressure lowering through NO synthase activation [s10]. 6. CYP450 modulation: Resveratrol inhibits CYP3A4 and other CYP450 enzymes, which may lead to clinically relevant drug interactions [s15].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Gastrointestinale Beschwerden (Übelkeit, Bauchschmerzen, Durchfall) Gastrointestinal symptoms occur more frequently at higher doses (>500 mg/day). Also documented in clinical studies with high doses (1000–2000 mg) [s15, s16]. | gelegentlich | leicht |
| Kopfschmerzen Reported as a side effect at higher doses in some clinical studies [s15]. | selten | leicht |
| Interaktion mit Blutgerinnungshemmern (erhöhtes Blutungsrisiko) Resveratrol inhibits platelet aggregation and can potentiate the effects of anticoagulants (e.g., warfarin, heparin) and antiplatelet agents [s15]. | theoretisch | moderat |
| Veränderung der Plasmaspiegel anderer Arzneimittel (CYP450-Hemmung) Resveratrol inhibits CYP3A4 and other CYP450 enzymes, which can lead to elevated plasma levels of substrates of these enzymes [s15]. | theoretisch | moderat |
| Estrogene Wirkung (theoretisch bei hormonsensitiven Erkrankungen) Resveratrol binds to estrogen receptors and can exert both agonistic and antagonistic effects. Clinical relevance at normal supplement doses unclear [s8]. | theoretisch | moderat |
Contraindications
Resveratrol binds estrogen receptors (ERα and ERβ) and may theoretically stimulate growth in estrogen-sensitive tumors. Caution advised pending further clinical data [s8, s15].
Combination with warfarin, heparin, or other anticoagulants increases bleeding risk through additive inhibition of platelet function [s15].
Insufficient safety data for pregnant and breastfeeding women. Estrogen-like activity theoretically relevant to pregnancy outcome [s15].
Resveratrol undergoes extensive hepatic metabolism; altered pharmacokinetics and possible accumulation are conceivable in severe hepatic insufficiency [s3, s15].
Interactions
Synergistic
Resveratrol activates SIRT1, which is NAD+-dependent; combined intake with NMN is purported to synergistically enhance NAD+ signaling pathways. Evidence to date is limited to preclinical and anecdotal data [s9].
Piperine inhibits glucuronidation of resveratrol and can significantly increase its bioavailability [s7].
Synergistic antioxidant and anti-inflammatory effects described in preclinical models; clinical data limited [s8].
Fisetin and resveratrol both act as senolytics and antioxidants. The combination may enhance clearance of senescent cells and produce additive anti-aging effects.
Resveratrol and curcumin synergistically complement each other in inhibiting inflammatory pathways – resveratrol via SIRT1/AMPK, curcumin via NF-κB. Preclinical data demonstrate antiproliferative synergy.
Resveratrol, curcumin, and berberine collectively modulate the PI3K/Akt/mTOR/GSK-3 signaling pathway. The combination may more broadly address metabolic and inflammatory processes.
Both substances are fat-soluble antioxidants with complementary mechanisms of action. The combination may enhance cellular protection against oxidative stress.
The combination of resveratrol and astaxanthin shows synergistic anti-aging effects in early studies. Resveratrol upregulates endogenous antioxidants, while astaxanthin acts directly as a potent free radical scavenger.
Resveratrol and spermidine both support autophagy via partially distinct pathways. The combination may synergistically enhance cellular clearance function.
Caution
Additive inhibition of platelet aggregation; increased bleeding risk. INR monitoring recommended [s15].
CYP3A4 inhibition by resveratrol may increase plasma levels of these medications and elevate toxicity risk [s15].
Estrogen receptor binding by resveratrol may interfere with the efficacy of hormonal therapies [s8, s15].
Additive antiplatelet effect increases bleeding risk [s15].
Studies
Tier A — High Evidence
Outcome: Metabolic markers (insulin, HbA1c, ALT) in obesity/overweight
Effect Size: Mixed results; small to moderate effect sizes
Outcome: Effect of resveratrol supplementation on SIRT1 levels in humans
Effect Size: Moderate positive effects on SIRT1 expression documented in RCTs
Outcome: Metabolic syndrome: HOMA-IR, total cholesterol, TG, LDL, systolic/diastolic blood pressure, hs-CRP
Effect Size: Significant reduction in HOMA-IR, TC, TG, LDL, SBP, DBP, and hs-CRP vs. placebo
Outcome: Safety, tolerability, plasma Aβ40/Aβ42 and CSF biomarkers in mild-to-moderate Alzheimer's disease
Effect Size: Well tolerated; plasma Aβ40 decline (possible brain penetration); no significant cognitive improvement
Tier B — Moderate Evidence
Outcome: Cerebral metabolic and perfusion changes in vascular cognitive impairment
Effect Size: Not yet completed; protocol published 2024
Outcome: Anti-inflammatory mechanisms of resveratrol (in vitro and in vivo)
Effect Size: Mechanistic review; no direct clinical effect sizes
Tier C — Low Evidence
Outcome: SIRT1 activation and lifespan extension in yeast, worms, Drosophila; translatability to humans unclear
Effect Size: Yeast lifespan extension +70%; no human endpoints
Community Evidence
Top reported benefits
- Possible synergy with NMN/NAD+ in anti-aging stack
- Subjectively perceived improved recovery in some users
- Antioxidant protection (not subjectively measurable, but popular)
- Combination with pterostilbene reported as an alternative
Top reported issues
- No noticeable short-term effects in most users
- Skepticism toward efficacy following disappointment from Sinclair hype
- Occasional gastrointestinal discomfort at higher doses
- Uncertainty about optimal dosage and formulation
In the biohacking community, resveratrol is largely viewed with skepticism since David Sinclair's claims have not been confirmed by robust human studies. Many users report no subjective improvements after 90-day self-experiments. Low bioavailability and the absence of everyday-relevant biomarker changes fuel this skepticism. Some users rely on liposomal formulations or piperine combinations without systematic evidence to support this approach.
Scientific Sources
- Commission Implementing Decision (EU) 2016/1190 authorising trans-resveratrol as a novel food ingredient
European Commission (2016). Official Journal of the European UnionALink - Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases (including meta-analysis data on metabolic markers)
Boccellino M, D'Angelo S, et al. (2025). PMC/NCBIALink - Effect of resveratrol supplementation on metabolic risk markers and anthropometric parameters in individuals with obesity or overweight: A systematic review and meta-analysis of randomized controlled trials
Saucedo-Toral A, Hernandez-Ruiz J, et al. (2024). Clinical Nutrition ESPENADOI - REsveratrol for VAscular cognitive impairment investigating cerebral Metabolism and Perfusion (REVAMP trial): a study protocol for a randomized, double-blind, placebo-controlled trial
Hattori Y, Minami M, Omae K, et al. (2024). Frontiers in NutritionADOI - A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease
Turner RS, Thomas RG, Craft S, et al. (2015). NeurologyAPMID:26362286DOI - Impact of Resveratrol Supplementation on Human Sirtuin 1: A GRADE-Assessed Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials
Authors not fully specified in search results (2025). Journal of the Academy of Nutrition and DieteticsADOI - Potential Adverse Effects of Resveratrol: A Literature Review
Shaito A, Posadino AM, Younes N, et al. (2020). International Journal of Molecular Sciences (PMC)BDOI - Resveratrol - Sicherheitsbewertung
DocMedicus Redaktion (2023). DocMedicus VitalstofflexikonCLink - High absorption but very low bioavailability of oral resveratrol in humans
Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle UK (2004). Drug Metabolism and DispositionAPMID:15333514DOI - Pharmacokinetic evaluation of two oral Resveratrol formulations in a randomized, open-label, crossover study in healthy fasting subjects
Nicht einzeln gelistet (Multi-Autoren-Studie) (2025). Scientific ReportsADOI - Frequently Asked Questions on Food Supplements
BfR (Bundesinstitut für Risikobewertung) (2019). BfRALink - Resveratrol - Overview: Bioavailability and Pharmacokinetics
Higdon J, Drake VJ, Delage B, et al. (2023). Linus Pauling Institute, Oregon State UniversityBLink - Resveratrol: Molecular Mechanisms, Health Benefits, and Prospects
Zhang Y, Chen M, Liu X, et al. (2025). PMC/NCBIBLink - Resveratrol-Formen im Vergleich: trans vs. cis – Wirkung, Stabilität und Bioverfügbarkeit
Nordic Oil Redaktion (2024). Nordic Oil BlogCLink - Physical and Pharmacokinetic Characterizations of trans-Resveratrol Encapsulated with Self-Assembling Lecithin-based Mixed Polymeric Micelles
Noorani L, Stenzel M, Liang R, et al. (2017). Scientific ReportsCDOI - Enhancing the bioavailability of resveratrol by combining it with piperine
Johnson JJ, Nihal M, Siddiqui IA, et al. (2011). Molecular Nutrition & Food ResearchAPMID:21714124DOI - Anti-Inflammatory Action and Mechanisms of Resveratrol
Maleki SJ, Crespo JF, Cabanillas B, et al. (2021). Molecules (PMC)BDOI - SIRT1, resveratrol and aging
Rogina B, Tissenbaum HA (2024). Frontiers in GeneticsBDOI
Community Sources
Storage
Unopened
Store cool, dry, and protected from light (below 25°C recommended). Trans-resveratrol is sensitive to light and oxidation [s5].
Opened
Seal the container tightly immediately after use. Exposure to UV light and oxygen accelerates isomerization to cis-resveratrol and loss of potency [s5].
Notes
Refrigeration is not required, but avoid heat sources (>30°C) and light. In powder form, avoid moisture.